Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind placebo-controlled study of TSG-02 for diabetic macular edema with inadequate response to anti-VEGF therapy
CTR20255055Phase 2Active
- Sponsor
- Shanghai Huiyu Biomedical Technology
- Start
- Mar 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of TSG-02 in diabetic macular edema (DME), sponsored by Shanghai Huiyu Biomedical Technology. Started Mar 2026; status: active.
02
Drugs
TSG-02
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20255055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255055.